Pharmacodynamics and Pharmacokinetics of Synthetic Mineralocorticoids and Glucocorticoids: Receptor Transactivation and Prereceptor Metabolism by 11β-hydroxysteroid-dehydrogenases

 

 Buy Article Permissions and Reprints

Abstract

Glucocorticoid (GC) and mineralocorticoid (MC) action in target tissues is determined by prereceptor metabolism by 11β-hydroxysteroid-dehydrogenases (HSDs) and receptor transactivation. We characterized these parameters for steroids often used in clinical practice. HSD activity was examined in human liver (HSD1) and kidney microsomes (HSD2) and in CHO cells stably transfected with both enzymes. GC and MC transcriptional activity was tested by luciferase assay in CV-1 cells transfected with human GC or MC receptor expression vectors. The 11-hydroxy-group is necessary for GC and MC receptor transactivation. As HSD2 oxidizes 11-hydroxysteroids to inactive 11-dehydrosteroids, GC and MC activity in HSD2-expressing tissues (kidney, colon) is regulated by this enzyme. As 9α-fluorination (such as in 9α-fluorocortisol) decreases oxidation by HSD2 and increases both GC and MC receptor transactivation, this modification leads to optimal, but non-selective transactivation of both receptors. Increased GC receptor and decreased MC receptor transactivation leading to more selective GC activity is reached using the following substituents: 16β-methyl (in betamethasone), 16α-methyl (in dexamethasone) and ▵1-dehydro-configuration (in prednisolone). Whereas the modifications in position 16 decrease oxidation by HSD2, the ▵1-dehydro-configuration increases HSD2-activity leading to an enhanced inactivation of prednisolone compared to all other steroids. 9α-fluorocortisol, the most frequently used substance for MC-substitution, seems to be the best choice of available steroids for this purpose. Whereas GC selectivity can be improved by hydrophobic substituents in position 16 and the ▵1-dehydro-configuration, maximal GC activity needs additional fluorination in position 9α (such as in dexamethasone). For GC therapy directed to HSD2-expressing organs, widely used prednisolone does not seem to be the optimal recommendation.

References

• 1 Fried J, Borman A. Synthetic derivates of cortical hormones.  Vitam Horm. 1958;  16 303-374
  PubMedGoogle Scholar
• 2 Ballard P L, Carter J P, Graham B S, Baxter J D. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man.  J Clin Endocrinol Metab. 1975;  41 290-304
  CrossrefPubMedGoogle Scholar
• 3 Agarwal M K, Mirshahi M. General overview of mineralocorticoid hormone action.  Pharmacol Ther. 1999;  84 273-326
  CrossrefPubMedGoogle Scholar
• 4 Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues.  Eur J Endocrinol. 2001;  144 87-97
  CrossrefPubMedGoogle Scholar
• 5 Whorwood C B, Franklyn J A, Sheppard M C, Stewart P M. Tissue localization of 11 beta-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor.  J Steroid Biochem Mol Biol. 1992;  41 21-28
  CrossrefPubMedGoogle Scholar
• 6 Nomura S, Fujitaka M, Sakura N, Ueda K. Circadian rhythms in plasma cortisone and cortisol and the cortisone/cortisol ratio.  Clin Chim Acta. 1997;  266 83-91
  CrossrefPubMedGoogle Scholar
• 7 Whorwood C B, Mason J I, Ricketts M L, Howie A J, Stewart P M. Detection of human 11β-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts.  Molecular and Cellular Endocrinology. 1995;  110 R7-R12
  CrossrefPubMedGoogle Scholar
• 8 Leckie C, Chapman K E, Edwards C RW, Seckl J R. LLC-PK₁ cells model 11β-hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors.  Endocrinology. 1995;  136 5561-5569
  CrossrefPubMedGoogle Scholar
• 9 Dunn J F, Nisula B C, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.  J Clin Endocrinol Metab. 1981;  53 58-68
  CrossrefPubMedGoogle Scholar
• 10 Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.  J Clin Endocrinol Metab. 1992;  75 259-264
  CrossrefPubMedGoogle Scholar
• 11 Diederich S, Hanke B, Burkhardt P, Müller M, Schöneshöfer M, Bähr V, Oelkers W. Metabolism of synthetic corticosteroids by 11β-hydroxysteroid- dehydrogenases in man.  Steroids. 1998;  63 271-277
  CrossrefPubMedGoogle Scholar
• 12 Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bähr V, Oelkers W. In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases: chenodeoxycholic acid selectively inhibits 11beta-HSD-I.  Eur J Endocrinol. 2000;  142 200-207
  CrossrefPubMedGoogle Scholar
• 13 Diederich S, Eigendorff E, Burkhard P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bähr V. 11β-hydroxysteroid dehydrogenase type 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids.  J Clin Endocrinol Metab. 2002;  87 5695-5701
  CrossrefPubMedGoogle Scholar
• 14 Diederich S, Hanke B, Oelkers W, Bähr V. Metabolism of dexamethasone in the human kidney: Nicotinamide adenine dinucleotide-dependent 11β-reduction.  J Clin Endocrinol Metab. 1997;  82 1598-1602
  CrossrefPubMedGoogle Scholar
• 15 Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bähr V. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor.  Eur J Endocrinol. 2002;  146 789-799
  CrossrefPubMedGoogle Scholar
• 16 Arriza J L, Weinberger C, Cerelli G, Glaser T M, Handelin B L, Housman D E, Evans R M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.  Science. 1987;  237 268-275
  CrossrefPubMedGoogle Scholar
• 17 Giguere V, Hollenberg S M, Rosenfeld M G, Evans R M. Functional domains of the human glucocorticoid receptor.  Cell. 1986;  46 645-652
  CrossrefPubMedGoogle Scholar
• 18 Chandler V L, Maler B A, Yamamoto K R. DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo.  Cell. 1983;  33 489-499
  CrossrefPubMedGoogle Scholar
• 19 Gellersen B, Kempf R, Telgmann R, DiMattia G E. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma.  Mol Endocrinol. 1994;  8 356-373
  CrossrefPubMedGoogle Scholar
• 20 Lorenz W W, McCann R O, Longiaru M, Cormier M J. Isolation and expression of a cDNA encoding Renilla reniformis luciferase.  Proc Natl Acad Sci U S A. 1991;  88 4438-4442
  PubMedGoogle Scholar
• 21 Jenkins J S, Sampson P A. Conversion of cortisone to cortisol and prednisone to prednisolone.  Br Med J. 1967;  2 205-207
  CrossrefPubMedGoogle Scholar
• 22 Diederich S, Quinkler M, Burkhardt P, Großmann C, Bähr V, Oelkers W. 11β-Hydroxysteroid-dehydrogenase isoforms: tissue distribution and implications for clinical medicine.  Eur J Clin Invest. 2000;  30 (Suppl 3) 21-27
  CrossrefPubMedGoogle Scholar
• 23 Escher G, Frey F J, Frey B M. 11beta-Hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney.  Endocrinology. 1994;  135 101-106
  CrossrefPubMedGoogle Scholar
• 24 Oelkers W, Buchen S, Diederich S, Krain J, Muhme S, Schöneshöfer M. Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency.  J Clin Endocrinol Metab. 1994;  78 928-932
  CrossrefPubMedGoogle Scholar
• 25 Ruers T JM, Buurman W A, van Boxtel C J, van der Linden C J, Kootstra G. Immunohistological observations in rat kidney allografts after local steroid administration.  J Exp Med. 1987;  166 1205-1220
  CrossrefPubMedGoogle Scholar
• 26 Ruers T JM, Buurman W A, Smits J FM, van der Linden C J, van Dongen J J, Struyker-Boudier H AJ, Kootstra G. Local treatment of renal allografts, a promising way to reduce the dosage of immunosuppressive drugs.  Transplantation. 1986;  41 156-161
  PubMedGoogle Scholar
• 27 Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists.  Proc Natl Acad Sci USA. 1998;  95 2973-2978
  CrossrefPubMedGoogle Scholar
• 28 Pratt W B, Toft D O. Steroid receptor interactions with heat shock protein and immunophilin chaperones.  Endocr Rev. 1997;  18 306-36
  CrossrefPubMedGoogle Scholar
• 29 Köppel H, Christ M, Yard B A, Bar P C, Van Der Woude F J, Wehling M. Nongenomic effects of aldosterone on human renal cells.  J Clin Endocrinol Metab. 2003;  88 1297-1302
  CrossrefPubMedGoogle Scholar
• 30 Adcock I M. Glucocorticoid-regulated transcription factors.  Pulm Pharmacol Ther. 2001;  14 211-219
  PubMedGoogle Scholar
• 31 Haynes R CJ. Adrenocorticotropic hormone: Adrenocortical steroids and their synthetic analogs: Inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman Gilman A, Rall TW, Nies AS, Tayler P (eds) The Pharmacological Basis of Therapeutics. New York; Pergamon Press 1990: 1431-1462
  Google Scholar

S. Diederich

Dept. of Endocrinology, Diabetes and Nutrition · Charité Universitätsmedizin Berlin

Campus Benjamin Franklin, Hindenburgdamm 30 · 12200 Berlin · Germany

Phone: + 49 (30) 8445-2114 ·

Fax: + 49 (30) 8445-4204